Resultados: 5

Risankizumab for previously treated moderately to severely active Crohn's disease

England. National Institute for Health and Care Excellence.

Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over....

Doença de Crohn/tratamento farmacológico, Anticorpos Monoclonais Humanizados/uso terapêutico, Custos de Cuidados de Saúde, Metanálise em Rede

Texto completo

AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease

Singh, Siddharth; Proctor, Deborah; Scott, Frank; Falck-Ytter, Yngve; Fuerstein, Joseph.

Gastroenterology; 160 (7), 2021

The incidence and prevalence of Crohn's disease (CD) is rising globally. Patients with moderate to severe CD are at high risk for needing surgery and hospitalization and for developing disease-related complications, corticosteroid dependence, and serious infections. Optimal management of outpatients with...

Doença de Crohn/diagnóstico, Doença de Crohn/tratamento farmacológico, Imunossupressores/uso terapêutico, Fístula/prevenção & controle, Doença de Crohn/complicações, Prática Clínica Baseada em Evidências

Texto completo

Crohn’s disease: management

England. National Institute for Health and Care Excellence.

This guideline covers the management of Crohn's disease in children, young people and adults. It aims to reduce people's symptoms and maintain or improve their quality of life....

Doença de Crohn/tratamento farmacológico, Doença de Crohn/complicações, Doença de Crohn/cirurgia, Qualidade da Assistência à Saúde/organização & administração, Glucocorticoides/uso terapêutico

Texto completo

Guía de práctica clínica para el tratamiento de la enfermedad de Crohn en población adulta

Clinical practice guideline for treatment of Crohn's Disease in adult population

Juliao B, Fabián; Grillo A, Carlos Fernando.

Rev. colomb. gastroenterol; 32 (supl 1), 2017

Generar recomendaciones informadas en la evidencia para el tratamiento de los pacientes con enfermedad de Crohn. Apoyar al tratamiento oportuno y seguro de los pacientes de enfermedad de Crohn considerando las minimización de secuelas y la hospitalización. Apoyar a los tomadores de decisiones a formula...

Doença de Crohn/tratamento farmacológico, Recidiva, Doença de Crohn/cirurgia, Fármacos Gastrointestinais/uso terapêutico, Anticorpos Monoclonais Humanizados/uso terapêutico, Fatores Imunológicos/uso terapêutico, Biomarcadores/análise

Texto completo

American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease

Terdiman, JP; Gruss, CB; Heidelbaugh, JJ; Sultan, S; Falck-Ytter, YT.

Gastroenterology; 145 (6), 2013

Fator de Necrose Tumoral alfa, Mercaptopurina, Azatioprina, Metotrexato, Doença de Crohn, Gastroenterologia, Mercaptopurina/uso terapêutico, Metotrexato/uso terapêutico, Indução de Remissão, Doença de Crohn/tratamento farmacológico, Fator de Necrose Tumoral alfa/antagonistas & inibidores

Texto completo